Fax: (011) 49 (0)511 532 9029
Significance of age in acute myeloid leukemia patients younger than 30 years
A common analysis of the pediatric trials AML-BFM 93/98 and the adult trials AMLCG 92/99 and AMLSG HD93/98A
Article first published online: 12 DEC 2007
Copyright © 2007 American Cancer Society
Volume 112, Issue 3, pages 562–571, 1 February 2008
How to Cite
Creutzig, U., Büchner, T., Sauerland, M. C., Zimmermann, M., Reinhardt, D., Döhner, H. and Schlenk, R. F. (2008), Significance of age in acute myeloid leukemia patients younger than 30 years. Cancer, 112: 562–571. doi: 10.1002/cncr.23220
- Issue published online: 18 JAN 2008
- Article first published online: 12 DEC 2007
- Manuscript Accepted: 24 AUG 2007
- Manuscript Revised: 31 JUL 2007
- Manuscript Received: 4 JUN 2007
- Deutsche Krebshilfe e.V.. Grant Numbers: M25/93/Ri1, 70-2315/Ri4, M17/92/Bü1, 70-2839-Bü4
- BMBF Competence Network Acute and Chronic Leukemias. Grant Numbers: 01GI 9976, 01GI9981
- 1National Cancer Institute. SEER Cancer Statistics Review, 1975–2000. Available from URL: http://seer.cancer.gov/csr/1975_2000 Accessed on March 12, 2007.
- 3Proposed revised criteria for the classification of acute myeloid leukemia. Ann Intern Med. 1985; 103: 626–629., , , et al.
- 96-Thioguanine, cytarabine, and daunorubicin (TAD) and high-dose cytarabine and mitoxantrone (HAM) for induction, TAD for consolidation, and either prolonged maintenance by reduced monthly TAD or TAD-HAM-TAD and one course of intensive consolidation by sequential HAM in adult patients at all ages with de novo acute myeloid leukemia (AML): a randomized trial of the German AML Cooperative Group. J Clin Oncol. 2003; 21: 4496–4504., , , et al.
- 10Double induction containing either 2 courses or one course of high-dose cytarabine plus mitoxantrone and postremission therapy by either autologous stem-cell transplantation or by prolonged maintenance for acute myeloid leukemia. J Clin Oncol. 2006; 24: 2480–2489., , , et al.
- 13Risk-adapted therapy in younger adults with acute myeloid leukemia: results of the AMLHD98A trial of the AMLSG. Blood. 2006; 108. Abstract 14., , , et al.
- 14Acute myelogenous leukaemia in children under 2 years — experiences of the West German AML Studies BFM-78, -83 and -87. Br J Cancer. 1992; 66( suppl XVIII): 63–67., , , et al.
- 30Acute myeloid leukemia (AML) in adolescents and young adults (AYAs): a comparison of outcomes between patients treated on childhood or adult protocols. Blood. 2001; 98: 462a–463a, Abstract 1934., , , et al.
- 31Early blast clearance by remission induction therapy is a major independent prognostic factor for both achievement of complete remission and long-term outcome in acute myeloid leukemia: data from the German AML Cooperative Group (AMLCG) 1992 Trial. Blood. 2003; 101: 64–70., , , et al.
- 33Randomized comparison of DAT versus ADE as induction chemotherapy in children and younger adults with acute myeloid leukemia. Results of the Medical Research Council's 10th AML trial (MRC AML10). Adult and Childhood Leukaemia Working Parties of the Medical Research Council. Blood. 1997; 89: 2311–2318., , , et al.
- 38A population-based study of 272 children with acute myeloid leukaemia treated on two consecutive protocols with different intensity: best outcome in girls, infants, and children with Down's syndrome. Nordic Society of Paediatric Haematology and Oncology (NOPHO). Br J Haematol. 1996; 94: 82–88., , , et al.
- 39Krebserkrankungen bei Kindern: Erfolg durch einheitliche Therapiekonzepte seit 25 Jahren. Dtsch Arztebl. 2003; 100: A842–A852., , , et al.